Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2010

References

• Joint United Nations Programme on HIV/AIDS (UNAIDS). AIDS epidemic update 2009. Geneva: World Health Organization/UNAIDS; 2009. Available at: http://www.unaids.org/en/media/unaids/contentassets/dataimport/pub/report/2009/jc1700_epi_update_2009_en.pdf (accessed: 12 March 2010).
   Google Scholar
• Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA 3rd, Whitehouse J, . Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999;341:385–93.
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Tatsioni A, Abrams EJ, Bulterys M, Coombs RW, Goedert JJ, . Maternal viral load and rate of disease progression among vertically HIV-1-infected children: an international meta-analysis. AIDS 2004;18:99–108.
   PubMed Web of Science ®Google Scholar
• Tubiana R, Le Chenadec J, Rouzioux C, Mandelbrot L, Hamrene K, Dollfus C, . Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load < 500 copies/ml at delivery: a case–control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis 2010;50:585–96.
   PubMed Web of Science ®Google Scholar
• Mandelbrot L, Mayaux MJ, Bongain A, Berrebi A, Moudoub-Jeanpetit Y, Benifla JL, . Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection Study Group. Am J Obstet Gynecol 1996;175:661–7.
   PubMed Web of Science ®Google Scholar
• Coll O, Suy A, Hernandez S, Pisa S, Lonca M, Thorne C, Borrell A. Prenatal diagnosis in human immunodeficiency virus-infected women: a new screening program for chromosomal anomalies. Am J Obstet Gynecol 2006;194:192–8.
   PubMed Web of Science ®Google Scholar
• Mandelbrot L, Jasseron C, Ekoukou D, Batallan A, Bongain A, Pannier E, . Amniocentesis and mother-to-child human immunodeficiency virus transmission in the Agence Nationale de Recherches sur le SIDA et les Hepatites Virales French Perinatal Cohort. Am J Obstet Gynecol 2009;200:160 e161–9.
   Web of Science ®Google Scholar
• Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, . Reduction of maternal–infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173–80.
   PubMed Web of Science ®Google Scholar
• The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1—a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999;340:977–87.
   PubMed Web of Science ®Google Scholar
• European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005;40:458–65.
   PubMed Web of Science ®Google Scholar
• Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS 2008;22: 973–81.
   PubMed Web of Science ®Google Scholar
• Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dollfus C, . Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008;22:289–99.
   PubMed Web of Science ®Google Scholar
• Boer K, England K, Godfried MH, Thorne C. Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe. HIV Med 2010;11:368–78.
   PubMed Web of Science ®Google Scholar
• Graham SM, Holte SE, Peshu NM, Richardson BA, Panteleeff DD, Jaoko WG, . Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 2007;21:501–7.
   PubMed Web of Science ®Google Scholar
• Mayaud P, Nagot N, Konate I, Ouedraogo A, Weiss HA, Foulongne V, . Effect of HIV-1 and antiretroviral therapy on herpes simplex virus type 2: a prospective study in African women. Sex Transm Infect 2008;84:332–7.
   Google Scholar
• O'Donovan D, Ariyoshi K, Milligan P, Ota M, Yamuah L, Sarge-Njie R, Whittle H. Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia. MRC/Gambia Government/University College London Medical School Working Group on Mother–Child Transmission of HIV. AIDS 2000;14:441–8.
   PubMed Web of Science ®Google Scholar
• Josephson F, Albert J, Flamholc L, Gisslen M, Karlstrom O, Moberg L, . Treatment of HIV infection: Swedish recommendations 2009. Scand J Infect Dis 2009;41:788–807.
   PubMed Web of Science ®Google Scholar
• Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35:538–9.
   PubMed Web of Science ®Google Scholar
• Barret B, Tardieu M, Rustin P, Lacroix C, Chabrol B, Desguerre I, . Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003;17:1769–85.
   PubMed Web of Science ®Google Scholar
• European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003;32:380–7.
   PubMed Web of Science ®Google Scholar
• The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 y of age in five United States cohorts. J Acquir Immune Defic Syndr 2000;25:261–8.
   PubMed Web of Science ®Google Scholar
• Tarantal AF, Castillo A, Ekert JE, Bischofberger N, Martin RB. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002;29:207–20.
   PubMed Web of Science ®Google Scholar
• Tarantal AF, Marthas ML, Shaw JP, Cundy K, Bischofberger N. Administration of 9-[2-®-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:323–33.
   PubMedGoogle Scholar
• Vigano A, Zuccotti GV, Stucchi S, Cerini C, Marinacci F, Salvini F, . Exposure during gestation to HAART, including tenofovir, does not impair bone status and metabolism in HIV-negative children born to HIV-positive mothers. Abstract 926. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, February 2010.
   Google Scholar
• Ripamonti D, Cattaneo D, d'Avolio A, Simiele M, Bonora S, Strobelt N, . Steady state pharmacokinetic of ritonavir-boosted atazanavir in 31 pregnant women before and after delivery. Abstract 907. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, February 2010.
   Google Scholar
• Mirochnick M, Stek A, Capparelli E, Best B, Rossi S, Burchett S, . Atazanavir pharmacokinetics with and without tenofovir during pregnancy. Abstract 941. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, February 2009.
   Google Scholar
• Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry international. Interim report for 1 January 1989 through 31 July 2009. Wilmington, NC: Registry Coordinating Center; 2009.
   Google Scholar
• Conradie F, Zorilla C, Josipovic D, Botes M, Osiyemi Y, Gomez M, . The safety, efficacy, and steady state pharmacokinetics of atazanavir/ritonavir (ATV/r) once daily given in combination with twice daily AZT/3TC during pregnancy: results of study AI424182. Abstract LBPEB06. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, July 2009.
   Google Scholar
• Burchett S, Best B, Mirochnick M, Hu C, Capparelli E, Holland D, . Tenofovir pharmacokinetics during pregnancy, at delivery and postpartum. Abstract 738b. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, February 2007.
   Google Scholar
• Natha M, Hay P, Taylor G, Brook G, Sarner L, Cunningham L, . Atazanavir use in pregnancy: a report of 33 cases. Abstract 750. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, February 2008.
   Google Scholar
• Ford N, Mofenson L, Kranzer K, Medu L, Frigati L, Mills EJ, Calmy A. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS 2010;24:1461–70.
   Web of Science ®Google Scholar
• Best BM, Capparelli EV. Implications of gender and pregnancy for antiretroviral drug dosing. Curr Opin HIV AIDS 2008;3:277–82.
   PubMedGoogle Scholar
• Izurieta P, Kakuda T, Clark A, Feys C, Witek J. Safety and pharmacokinetics of etravirine in pregnant HIV-infected women. PE4.1/6. 12^th European AIDS Conference (EACS 2009). Cologne, Germany, November 2009.
   Google Scholar
• Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, . Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007;21:2409–15.
   PubMed Web of Science ®Google Scholar
• Dumond JB, Patterson KB, Pecha AL, Werner RE, Andrews E, Damle B, . Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr 2009;51:546–53.
   PubMed Web of Science ®Google Scholar
• Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, . Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 2007;21:1899–907.
   PubMed Web of Science ®Google Scholar
• Min SS, Corbett AH, Rezk N, Cu-Uvin S, Fiscus SA, Petch L, . Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr 2004;37: 1577–80.
   PubMed Web of Science ®Google Scholar
• Jones A, Talameh J, Patterson K, Rezk N, Prince H, Kashuba A. First-dose and steady-state pharmacokinetics (PK) of raltegravir (RAL) in the genital tract (GT) of HIV uninfected women. Abstract O_06. 10^th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, the Netherlands, April 2009.
   Google Scholar
• El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, . CD4+count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355: 2283–96.
   PubMed Web of Science ®Google Scholar